statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance

BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Buy" from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has received an average recommendation of "Buy" from the seven ratings firms that are presently covering the stock, Marketbeat reports...

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual...

Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) & Adverum Biotechnologies (NASDAQ:ADVM)

Adverum Biotechnologies (NASDAQ:ADVM  Get Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX  Get Free Report) are both small-cap medical companies, but which is the superior...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $13.29 Consensus PT from Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX  Get Free Report) have received an average recommendation of Buy from the seven research firms that are presently covering...

RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors...

BioCryst Pharmaceuticals (BCRX, $5.51) Stochastic Oscillator left the oversold zone on March 04, 2024

This is a signal that BCRX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

ELCO Management Co. LLC Raises Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

ELCO Management Co. LLC grew its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX  Free Report) by 134.9% during the third quarter, Holdings Channel reports. The institutional...

BioCryst Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Volume	2.36M
52-Wk High	$7.88
52-Wk Low	$4.03

BCRX Biocryst Pharmaceuticals Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals